Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease

American Journal of Hematology

Volumn 90, Issue 1, 2015, Pages E17-E21

  Muendlein, Axel ^a   Kinz, Elena ^a,b   Gasser, Klaus ^a,b,c   Leiherer, Andreas ^a,b,d   Rein, Philipp ^a,c   Saely, Christoph H ^a,b,c   Grallert, Harald ^e   Peters, Annette ^e,f   Fraunberger, Peter ^d   Drexel, Heinz ^a,b,c,g   Lang, Alois H ^c  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^c Academic Teaching Hospital Feldkirch   (Austria)

^d Medical Central Laboratory   (Austria)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^g DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; JANUS KINASE 2; JAK2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; VERY ELDERLY; CASE CONTROL STUDY; ECHOGRAPHY; ENZYMOLOGY; GENETICS; GENOTYPING TECHNIQUE; MULTIVARIATE ANALYSIS; MUTATION; PERIPHERAL ARTERIAL DISEASE; REGRESSION ANALYSIS;

AGED; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENOTYPING TECHNIQUES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PERIPHERAL ARTERIAL DISEASE; REGRESSION ANALYSIS;

EID: 84919663556     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23874     Document Type: Article

References (56)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease [(PAD) lower extremity, renal, mesenteric, and abdominal aortic]: A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463-e654.
2. Welten GM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral arterial disease: A comparison in patients with coronary artery disease. J Am Coll Cardiol 2008;51:1588-1596.
3. Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease. Circulation 2010;122:1862-1875.
4. Signorelli SS, Fiore V, Malaponte G. Inflammation and peripheral arterial disease: The value of circulating biomarkers (Review). Int J Mol Med 2014;33:777-783.
5. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 2009; 27:165-197.
6. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011;12:204-212.
7. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999; 340:115-126.
8. Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart 2014;100:414-423.
9. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281-1283.
10. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012;30:1005-1014.
11. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell 2002;109 Suppl:S121-S131.
12. Grote K, Luchtefeld M, Schieffer B. JANUS under stress-Role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol 2005;43:357-363.
13. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012;119:3219-3225.
14. Marrero MB. Introduction to JAK/STAT signaling and the vasculature. Vascul Pharmacol 2005;43:307-309.
15. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
16. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
17. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
18. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-2466.
19. Rumi E, Elena C, Passamonti F. Mutational status of myeloproliferative neoplasms. Crit Rev Eukaryot Gene Expr 2010;20:61-76.
20. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
21. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
22. Martinaud C, Brisou P, Mozziconacci MJ. Is the JAK2(V617F) mutation detectable in healthy volunteers? Am J Hematol 2010; 85:287-288.
23. Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 2011;96:450-453.
24. Sidon P, El Housni H, Dessars B, Heimann P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006;20:1622.
25. Rapado I, Albizua E, Ayala R, et al. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol 2008;87:741-749.
26. Weinberg I, Borohovitz A, Krichevsky S, et al. Janus Kinase V617F mutation in cigarette smokers. Am J Hematol 2012;87:5-8.
27. Xu X, Zhang Q, Luo J, et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 2007;109:339-342.
28. Muendlein A, Gasser K, Kinz E, et al. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients. Am J Hematol 2014;89:295-301.
29. Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-7451.
30. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-1210.
31. Azam SM, Carman TL. Diagnostic approach to peripheral arterial disease. Cardiol Clin 2011;29:319-329.
32. Vonbank A, Saely CH, Rein P, Drexel H. Insulin resistance is significantly associated with the metabolic syndrome, but not with sonographically proven peripheral arterial disease. Cardiovasc Diabetol 2013;12:106.
33. Holle R, Happich M, Lowel H, Wichmann HE. KORA-A research platform for population based health research. Gesundheitswesen 2005;67 Suppl 1:S19-S25.
34. Wichmann HE, Gieger C, Illig T. KORA-gen--resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 2005;67 Suppl 1:S26-S30.
35. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279-2284.
36. Antonioli E, Guglielmelli P, Poli G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008;93:41-48.
37. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-1266.
38. Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-C97.
39. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 2000;87:1195-1201.
40. Johnson JL. Emerging regulators of vascular smooth muscle cell function in the development and progression of atherosclerosis. Cardiovasc Res 2014;103:452-460.
41. Ait-Oufella H, Sage AP, Mallat Z, Tedgui A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res 2014;114:1640-1660.
42. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. Int J Cardiol 2013;168:5126-5134.
43. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-428.
44. Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: Different role of C-reactive protein and pentraxin 3. Haematologica 2011;96:315-318.
45. Stone WL, Krishnan K, Campbell SE, Palau VE. The role of antioxidants and pro-oxidants in colon cancer. World J Gastrointest Oncol 2014;6:55-66.
46. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes-A review. Diabet Med 2010;27:4-14.
47. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: Mechanisms and potential targets. Nutrients 2013;5:1218-1240.
48. Siasos G, Tousoulis D, Michalea S, et al. Smoking and atherosclerosis: Mechanisms of disease and new therapeutic approaches. Curr Med Chem, 2014; in press.
49. Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: Role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006;391:499-510.
50. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 2013;37:214-220.
51. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J 2003;17:1195-1214.
52. Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011;29:2897-2903.
53. Fleischman AG, Aichberger KJ, Luty SB, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011;118:6392-6398.
54. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 2002;447:1-9.
55. Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer 2014;111:61-67.
56. Shi X, Ding M, Dong Z, et al. Antioxidant properties of aspirin: Characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol Cell Biochem 1999;199:93-102.